[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516331":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":39,"responsibleParty":58,"collaborators":18,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TMS-EEG Arm","EXPERIMENTAL","This arm will undergo TMS-EEG during the study.",[13],"Device: Transcranial Magnetic Stimulation-Electroencephalography",{"label":15,"type":16,"description":17,"interventionNames":18},"Non-TMS-EEG Arm","NO_INTERVENTION","This arm will not undergo TMS-EEG during the study.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Transcranial Magnetic Stimulation-Electroencephalography","Transcranial magnetic stimulation of the cerebral cortex and measurement of TMS-evoked potentials in the EEG.",[9],[26],"TMS-EEG",[28],{"name":29,"affiliation":5,"role":30},"Emery N Brown, MD, PhD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","+1 617-324-1879","ebrown@mgh.harvard.edu",{"name":37,"role":33,"phone":18,"phoneExt":18,"email":38},"David Schreier, MD, PhD","dschreier@mgh.harvard.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-71.05977,42.35843,{"lat":51,"lon":50},[54,56,57],{"name":29,"role":33,"phone":55,"phoneExt":18,"email":35},"617-324-1879",{"name":37,"role":33,"phone":18,"phoneExt":18,"email":38},{"name":29,"role":30,"phone":18,"phoneExt":18,"email":18},{"type":30,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Emery Brown","Professor of Anesthesia","100516331","recovery-from-dexmedetomidine-induced-unconsciousness-100516331",false,"NCT06003127","REcovery From DEXmedetomidine-induced Unconsciousness","REDEX","Inclusion Criteria:\n\n* Between the ages of 18 to 65\n* Normal body weight and habitus, body mass index (BMI) 18 to 30 kg\u002Fm2\n* Non-smoker\n* No history of taking stimulants or substance abuse\n* For women: either use of hormonal contraception, or \\> 45 years old and last menstrual period \\> 12 months ago in the absence of any contraceptives.\n* American Society of Anesthesiologists (ASA) physical status classification 1 (ASA 1)\n* Fluent in English (sufficient to communicate with the study team and understand the consent form)\n\nExclusion Criteria:\n\n* Neurologic: epilepsy or positive history of a seizure, stroke, central disorders of hypersomnolence, neuroimmunological disorder (e.g. multiple sclerosis), Meniere's disease, Parkinson's disease, peripheral neuropathy, no significant visual or hearing impairments, findings in the clinical examination suggesting a neurologic disorder\n* Psychiatric: history or treatment for an active psychiatric problem (including Attention-Deficit \u002F Hyperactivity Disorder (ADHD) and anxiety disorder)\n* Cardiovascular: hypertension, symptomatic hypotension or bradycardia, myocardial infarction, coronary artery disease, peripheral vascular disease, dysrhythmias, congestive heart failure, cardiomyopathy, valvular disease, familial history of sudden cardiac death\n* Respiratory: bronchitis, asthma, chronic obstructive pulmonary disease, smoking, shortness of breath, sleep apnea\n* Gastrointestinal: esophageal reflux, hiatal hernia, ulcer\n* Hepatic: hepatitis, jaundice, ascites\n* Renal: acute or chronic severe renal insufficiency\n* Reproductive: pregnancy, breast-feeding\n* Endocrine: diabetes, thyroid disease, adrenal gland disease\n* Hematologic: blood dyscrasias, anemia, coagulopathies\n* Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or family history of malignant hyperthermia\n* Medications: regular use of prescription and non-prescription medications expected to affect central nervous function, anticoagulant or thrombocyte-aggregation inhibiting therapy; exception: oral hormonal contraception\n* Allergies: dexmedetomidine, phenylephrine, betablockers (including labetalol and esmolol), hydralazine, glycopyrrolate\n\nPotential participants will not be enrolled in our study if they fail to pass a standard drug screening test (toxicology).",true,"ALL","18 Years","65 Years",{"count":73,"type":74},12,"ESTIMATED","INTERVENTIONAL",[77],"NA","This pilot study in healthy volunteers aims to determine if biological sex has an impact on recovery from dexmedetomidine-induced unconsciousness, and if transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) can be used to measure brain complexity during dexmedetomidine sedation without arousing study participants.",[80,81,82],"Anesthesia","Healthy","Consciousness, Level Altered",[84,85,86,87],"Dexmedetomidine","EEG","Transcranial magnetic stimulation","Cognition","2026-01-20",{"date":90,"type":91},"2026-01-22","ACTUAL",{"date":93,"type":91},"2024-11-15",{"date":95,"type":74},"2026-12",{"name":5,"class":6},1]